Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography

Journal of Pharmacological and Toxicological Methods

Volumn 40, Issue 4, 1998, Pages 235-239

  Granda, Brian W ^a,b   Giancarlo, Gina M ^a,b   Von Moltke, Lisa L ^a,b   Greenblatt, David J ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Drug interactions; Protease inhibitors; Ritonavir

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CALIBRATION; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

ANIMALS; BRAIN CHEMISTRY; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIVER; MICE; REPRODUCIBILITY OF RESULTS; RITONAVIR;

EID: 0032317247     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(99)00013-1     Document Type: Article

References (16)

1. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard J (1996) Effect of ritonavir on the pharmacokinetics of desipramine. Int Conf AIDS 11:89 (abstract Mo.B.1201).
2. Cato A, Cavanaugh JH, Shi H, Hsu A, Leonard J, Granneman GR (1998) The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharm Ther 63:414-421.
3. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires K, Deutsch PJ, Emini EE (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
4. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, de Lomas JG, Delgado R, Borleffs JCC, Hsu A, Valdes JM, Boucher CAB, Cooper DA (1995) A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-protease. N Engl J Med 333:1528-1533.
5. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Krempf DJ, Thomas SB, Surber BW (1997) Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 25:489-501.
6. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
7. Hsu A, Granneman GF, Wutt G, Locke C, Denissen, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, DeCourt JP, Fourtillan JB, Girault J, Leonard JM (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41:898-905.
8. Kim RB, Fromm MF, Wandel C, Leake B, Wood A, Rodin DM, Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
9. Marsh KC, Eider E, McDonald E (1997) Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatog B 704:307-313.
10. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Brekenridge AM, Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
11. Merry C, Barry MG, Mulcahy F, Tjia JF, Halifax KL, Heavey J, Kelly C, Back DJ (1998) Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients. AIDS 12: 325-326.
12. Quellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR (1996) Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Int Conf AIDS 11:88 (abstract Mo.B.1198).
13. Roberts NA (1995) Drug resistance patterns of saquinavir and other HIV protinease inhibitors. AIDS 9(suppl 2):S27-S32.
14. Sahai J (1996) Risks and synergies from drug interactions. AIDS 10(suppl 1):S21-S25.
15. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI (1998a) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106-111.
16. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI (1998b) Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 87:1184-1189.